Direct-to-consumer (DTC) genetic testing kits are services purchased by consumers through print advertisements, television, and the Internet. These kits possess the ability to detect and identify mutated strains of DNA that could evolve into chronic diseases. It could provide consumers with a forewarning to the possibility of attaining hereditary diseases due to the family medical history and genetic structure. Types of testing kits are individual health planning, medical precision tests, genome data bank, restrictive traits, and comprehensive genome test models.
Browse full research report :
Easy Detection of Rare Diseases
The end users that can sell DTC genetic testing kits are Internet, doctor’s office, and others. The Internet segment is expected to gain a large market share till 2022 due to easy access to Internet via smartphones and laptops. In addition, the relaxation of certain policies by regulatory agencies such as the U.S. Food and Drug Administration (FDA) has provided relief to companies such as 23andMe and Pathway Genomics. The Breast Cancer (BRCA) test by Color Genomics can detect the presence of BRCA1 and BRCA2 genes, the main cause of breast cancer in women and save lives.
The doctor’s office segment is predicted to gain a fair market share by 2022 due to test kit manufacturers allying with physicians or geneticists to sell their kits. In addition, these specialists can offer a comprehensive understanding of genetic test results. Patients can benefit from this advice and take appropriate steps to reduce the probability of gaining hereditary diseases.
Market Outlook
The global direct-to-consumer (DTC) genetic testing market is projected to experience a steady growth rate over the forecast period (2016-2022), according to a report on Radiant Insights, Inc. The demand for genetic tests to identify chronic diseases at an early stage is expected to be the key driving factor of the market.
The increasing healthcare costs, emphasis on personalized disease management, and consumer awareness of these tests due to Internet and television are factors predicted to spur market growth over the forecast period. Development of non-invasive tests to detect hereditary diseases is expected to open up new avenues for growth. Key market players include Navigenics, Inc.; Genetrainer; deCODE genetics Inc.; and 23andMe.
Free request sample :
No comments:
Post a Comment